title: Rosiglitazone-induced granulomatous hepatitis.
abstract: Granulomatous hepatitis has many causes. Drugs are an important etiologic factor. Several oral hypoglycemic agents are available for treatment of type II diabetes. Rosiglitazone, a thiazolidinedione, is a newer agent in this class. It has not been shown to be hepatotoxic in the premarketing trials. However, a few case reports have implicated it as a cause of acute hepatocellular injury. The authors report a case of granulomatous hepatitis associated with use of rosiglitazone. Liver function tests should be done regularly to monitor patients on this medication.
authors.affiliation: Department of Gastroenterology, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212, U.S.A.
authors.forename: Manish
authors.initials: M
authors.lastname: Dhawan
authors.forename: Radheshyam
authors.initials: R
authors.lastname: Agrawal
authors.forename: Jan
authors.initials: J
authors.lastname: Ravi
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Gulati
authors.forename: Jan
authors.initials: J
authors.lastname: Silverman
authors.forename: Girija
authors.initials: G
authors.lastname: Nathan
authors.forename: Stephen
authors.initials: S
authors.lastname: Raab
authors.forename: George
authors.initials: G
authors.lastname: Brodmerkel
mesh_terms: D000328:Adult; D001706:Biopsy; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000473:pathology; D006099:Granuloma / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000473:pathology; D008297:Male; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use; D045162:Thiazolidinediones; D013997:Time Factors
chemical_list: D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone